Palonosetron and Dexamethasone for the Prevention of Nausea and Vomiting in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2013 Dec 10

PMID 24317849

Citations 2

Authors

Su-Peng Yeh

Woei-Chung Lo

Ching-Yun Hsieh

Li-Yuan Bai

Ching-Chan Lin

Po-Han Lin

Chen-Yuan Lin

Yu-Min Liao

Chang-Fang Chiu

Affiliations

Soon will be listed here.

Abstract

Purpose: The primary aim of this study was to evaluate the efficacy of palonosetron combined with dexamethasone in the prevention of vomiting, and especially nausea, in patients receiving allogeneic stem cell transplantation.

Methods: Palonosetron 0.25 mg was given to 27 patients receiving allogeneic transplantation on the first day of conditioning, and then every other day during the entire conditioning period. Dexamethasone was given daily also during conditioning. Vomiting and nausea were recorded daily according to CTCAE version 4.0 from the start of conditioning to Day 7 after transplantation. In addition, MASCC antiemetic tool (MAT) was also used in parallel to evaluate the intensity of nausea.

Results: The treatment was well tolerated; 25.9 and 40.7 % of the patients had grade 2/3 vomiting and nausea respectively during conditioning. The incidences of grade 2/3 vomiting and nausea were even higher in the first week after transplantation (40.7 and 51.8 %, respectively). The score of MAT correlated well with the grade of CTCAE. However, the difference in the mean intensity of nausea between period of conditioning and the first week after HSCT was significant only by using MAT (0.96 ± 1.829 vs. 3.81 ± 3.386, p=0.001) but not CTCAE (1.26 ± 0.903 vs. 1.63 ±0.967, p=0.152).

Conclusion: Palonosetron combined with dexamethasone is effective in preventing vomiting during conditioning. However, more effort should be made to alleviate nausea during conditioning and both nausea and vomiting in the first week after transplantation. Furthermore, MAT has a higher discriminant power than CTCAE in assessing the intensity of nausea in patients receiving allogeneic transplantation.

Citing Articles

Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation.

Yuda S, Fuji S, Savani B, Gatwood K Clin Hematol Int. 2022; 4(3):89-98.

PMID: 36131129 PMC: 9492824. DOI: 10.1007/s44228-022-00012-8.

Psychometric assessment of the Chinese version of the MASCC Antiemesis Tool (MAT) for measuring chemotherapy-induced nausea and vomiting.

Tan J, Suen L, Molassiotis A Support Care Cancer. 2016; 24(9):3729-37.

PMID: 27039204 DOI: 10.1007/s00520-016-3181-7.

References

Lopez-Jimenez J, Martin-Ballesteros E, Sureda A, Uralburu C, Lorenzo I, Del Campo R . Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica. 2006; 91(1):84-91. View

Walsh T, Morris A, Holle L, Callander N, Bradshaw P, Valley A . Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial. Bone Marrow Transplant. 2004; 34(11):963-8. DOI: 10.1038/sj.bmt.1704714. View

Fox S, Einhorn L, Cox E, Powell N, Abdy A . Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol. 1993; 11(12):2391-5. DOI: 10.1200/JCO.1993.11.12.2391. View

Bloechl-Daum B, Deuson R, Mavros P, Hansen M, Herrstedt J . Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006; 24(27):4472-8. DOI: 10.1200/JCO.2006.05.6382. View

Einhorn L, Rapoport B, Koeller J, Grunberg S, Feyer P, Rittenberg C . Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer. 2004; 13(2):112-6. DOI: 10.1007/s00520-004-0704-4. View

Griffin A, Butow P, Coates A, Childs A, Ellis P, Dunn S . On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996; 7(2):189-95. DOI: 10.1093/oxfordjournals.annonc.a010548. View

Grunberg S, Osoba D, Hesketh P, Gralla R, Borjeson S, Rapoport B . Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update. Support Care Cancer. 2004; 13(2):80-4. DOI: 10.1007/s00520-004-0718-y. View

Mattiuzzi G, Cortes J, Blamble D, Bekele B, Xiao L, Cabanillas M . Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer. 2011; 116(24):5659-66. PMC: 4185295. DOI: 10.1002/cncr.25365. View

Glotzbecker B, Duncan C, Alyea 3rd E, Campbell B, Soiffer R . Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol Blood Marrow Transplant. 2011; 18(7):989-1006. DOI: 10.1016/j.bbmt.2011.11.029. View

10.

Sledge Jr G, Einhorn L, Nagy C, House K . Phase III double-blind comparison of intravenous ondansetron and metoclopramide as antiemetic therapy for patients receiving multiple-day cisplatin-based chemotherapy. Cancer. 1992; 70(10):2524-8. DOI: 10.1002/1097-0142(19921115)70:10<2524::aid-cncr2820701022>3.0.co;2-z. View

11.

Giralt S, Mangan K, Maziarz R, Bubalo J, Beveridge R, Hurd D . Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Ann Oncol. 2010; 22(4):939-946. DOI: 10.1093/annonc/mdq457. View

12.

Fakhfouri G, Rahimian R, Daneshmand A, Bahremand A, Rasouli M, Dehpour A . Granisetron ameliorates acetic acid-induced colitis in rats. Hum Exp Toxicol. 2010; 29(4):321-8. DOI: 10.1177/0960327110362702. View

13.

Rojas C, Thomas A, Alt J, Stathis M, Zhang J, Rubenstein E . Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2009; 626(2-3):193-9. DOI: 10.1016/j.ejphar.2009.10.002. View

14.

Fiebich B, Akundi R, Lieb K, Candelario-Jalil E, Gmeiner D, Haus U . Antiinflammatory effects of 5-HT3 receptor antagonists in lipopolysaccharide-stimulated primary human monocytes. Scand J Rheumatol Suppl. 2004; 119:28-32. View

15.

Matsuoka S, Okamoto S, Watanabe R, Mori T, Nagayama H, Hamano Y . Granisetron plus dexamethasone versus granisetron alone in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Int J Hematol. 2003; 77(1):86-90. DOI: 10.1007/BF02982608. View

16.

Muller W, Fiebich B, Stratz T . New treatment options using 5-HT3 receptor antagonists in rheumatic diseases. Curr Top Med Chem. 2006; 6(18):2035-42. DOI: 10.2174/156802606778522122. View

17.

Fauser A, Pizzocaro G, Schueller J, Khayat D, Wilkinson P . A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting. Support Care Cancer. 2000; 8(1):49-54. DOI: 10.1007/s005209900090. View

18.

Li N, Ghia J, Wang H, McClemens J, Cote F, Suehiro Y . Serotonin activates dendritic cell function in the context of gut inflammation. Am J Pathol. 2011; 178(2):662-71. PMC: 3069907. DOI: 10.1016/j.ajpath.2010.10.028. View

19.

Fisher S, Kiley K, Porter N, Stiff P . Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Biol Blood Marrow Transplant. 2002; 7(11):596-603. DOI: 10.1053/bbmt.2001.v7.pm11760147. View

20.

Oo T, Hesketh P . Drug insight: New antiemetics in the management of chemotherapy-induced nausea and vomiting. Nat Clin Pract Oncol. 2005; 2(4):196-201. DOI: 10.1038/ncponc0132. View